Drug Profile
Melanoma DNA vaccine - Vical
Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA); Vical
- Developer Vical
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 31 Oct 2001 Discontinued - Phase-II for Malignant melanoma in USA (Parenteral)
- 18 Aug 1998 Phase-II clinical trials for Malignant melanoma in USA (Parenteral)
- 05 Aug 1998 New profile